01.01.06
Indication: Alzheimer’s disease
Source: 21st International Conference of Alzheimer’s Disease International, Istanbul, Turkey
Research: Three hundred and ninety-five outpatients with mild to moderate dementia and neuropsychiatric symptoms (such as depressed mood, anxiety, irritability and indifference) participated in this study. According to researchers, patients with these symptoms represent the overwhelming majority of Alzheimer’s cases in clinical practice. Patients received either 240 mg of EGb 761 or placebo daily. The primary outcome measure in the cognitive domain was the SKT test battery, which is an internationally validated rating scale for dementia. In the neuropsychiatric domain the Neuropsychiatric Inventory (NPI) and the Hamilton Rating Scale for Depression (HAMD) were applied.
Results: After 22 weeks, patients given EGb 761 showed clear improvement and a highly significant difference of 4.5 points compared to those receiving placebo. Similar statistically significant improvements were found for the EGb 761 group on all secondary outcome measures. EGb 761 was also well tolerated.
Source: 21st International Conference of Alzheimer’s Disease International, Istanbul, Turkey
Research: Three hundred and ninety-five outpatients with mild to moderate dementia and neuropsychiatric symptoms (such as depressed mood, anxiety, irritability and indifference) participated in this study. According to researchers, patients with these symptoms represent the overwhelming majority of Alzheimer’s cases in clinical practice. Patients received either 240 mg of EGb 761 or placebo daily. The primary outcome measure in the cognitive domain was the SKT test battery, which is an internationally validated rating scale for dementia. In the neuropsychiatric domain the Neuropsychiatric Inventory (NPI) and the Hamilton Rating Scale for Depression (HAMD) were applied.
Results: After 22 weeks, patients given EGb 761 showed clear improvement and a highly significant difference of 4.5 points compared to those receiving placebo. Similar statistically significant improvements were found for the EGb 761 group on all secondary outcome measures. EGb 761 was also well tolerated.
